Eli Lilly and Company has been in business more than 135 years. The global, research-based company was founded in May 1876 by Colonel Eli Lilly in Indianapolis, Ind., in the Midwestern section of the United States. A 38-year-old pharmaceutical chemist and a veteran of the U.S. Civil War, Colonel Lilly was frustrated by the poorly prepared, often ineffective medicines of his day. Consequently, he made these commitments to himself and to society:
◦ He would found a company that manufactured pharmaceutical products of the highest possible quality.
◦ His company would develop only medicines that would be dispensed at the suggestion of physicians rather than by eloquent sideshow hucksters.
◦ Lilly pharmaceuticals would be based on the best science of the day.
Although his business flourished, Colonel Lilly wasn’t satisfied with the traditional methods of testing the quality of his products. In 1886, he hired a young chemist to function as a full-time scientist, using and improving upon the newest techniques for quality evaluation. Together, they laid the foundation for the Lilly tradition: a dedication that first concentrated on the quality of existing products and later expanded to include the discovery and development of new and better pharmaceuticals.
Eventually, Colonel Lilly’s son, Josiah K. Lilly Sr., and two grandsons, Eli Lilly and Josiah K. Lilly Jr., each served as president of the company, and each contributed a distinctive approach to management. Together, these management styles established a corporate culture in which Lilly employees were viewed as the company’s most valuable assets, a belief that is still the cornerstone of our corporate philosophy. For well more than a century, Lilly employees have worked to discover and develop important medical breakthroughs.
Torre Ocidente, Rua Galileu Galilei,
N.º 2, Piso 7 Fracção A/D,
1500-392 LISBOA
Telefone: +351 21 412 66 00
Fax: +351 21 410 99 44
Endereço: pt.geral@lilly.com
Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach…
António Leão, General Manager of Lilly, Portugal, talks about adapting to a challenging economic environment, as well as the importance of the company’s portfolio and pipeline, in Portugal today. Why…
Nelson Pires provides an insightful update on Portugual’s pharmaceutical market evolution as well as Jaba Recordati’s ambitious Portuguese affiliate. Pires shares that diversification is one technique of navigating the market,…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Medicinalia Cormedica is the leading Portuguese distributor of medical devices. Antonio Cabral, who has led the business in Portugal for almost a decade, introduces the company, explains its business model…
Carla Benedito, general manager of Shire Portugal, provides useful insight into the rare diseases landscape in Portugal. Carla discusses market access models for innovative and rare treatments, encouraging dialogue between…
Olga Insua, the new American general manager for Novo Nordisk Portugal, fresh off the plane from Spain, provides an exclusive insight into her impressive career at the company, the blending…
Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach…
Salvador Fernandes, Ralph Steffen and Sofia Fernandes, chairman, production manager, and marketing manager respectively, discuss Sidefarma’s positioning in the Portuguese manufacturing landscape, and the strong relationship evolving between the government…
Antonio Portela, seven years into leading the Bial operation in Portugal, shares his views on internationalization and how to maintain a stable company culture when approaching new and diverse markets.…
Cristina Campos is well known on the Portuguese pharmaceutical circuit, directing the affiliate of market leader, Novartis, and holding a position as vice-president at APIFARMA, the Portuguese Pharmaceutical Association. In…
Filipe Assoreira and José Albuquerque, president and secretary general respectively of P-Bio – Portugal’s bioindustry association – discuss the importance of innovation to the biopharmaceutical industry and the importance of…
Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception…
João Vasconcelos was the Secretary of State for Industry in Portugal over a two year period, terminating in July 2017, over which time he laid the foundations for Startup Portugal…
See our Cookie Privacy Policy Here
